Literature DB >> 30476873

Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.

Ieva Eskyte1, Ana Manzano2, George Pepper2, Sue Pavitt2, Helen Ford2, Hilary Bekker2, Jeremy Chataway2, Klaus Schmierer2, David Meads2, Edward Webb2, Barbara Potrata2.   

Abstract

BACKGROUND: Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system that mainly affects young adults. While there is no cure for MS, disease modifying treatments (DMTs) reduce the relapse rate and partial accrual of disability. More effective DMTs may have higher risks including life-threatening infections or secondary autoimmunity. The complexity and novelty of available treatments cause challenges for clinicians when prescribing treatments and for people with MS (PwMS) when deciding what trade-offs they are willing and ready to make.
OBJECTIVE: To explore the experience of people with relapsing remitting MS (PwRRMS) and their perspectives in choosing treatments.
METHODS: Critical interpretive synthesis was employed to review and synthesis the published literature. Eighty-three publications were selected in a multi-step systematic process.
RESULTS: Findings are presented in four interrelated areas: the influence of the clinical evidence-base in decision making; the meaning of DMT efficacy for PwRRMS; the influence of models of decision-making and information acquisition practices in PwRRMS; and the importance of psychosocial dimensions in DMT decision making. Synthesis of the findings revealed that alongside medical and individual reasoning, contextual circumstances play an important role in making treatment decisions.
CONCLUSION: This review identifies and explains the importance of diverse contextual circumstances (clinical, social, psychological) that are important for PwRRMS when making treatment decisions. The findings demonstrate the importance of eliciting, understanding and addressing such contextual factors.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Decision-making; Decision-support techniques; Disease-modifying treatments; Multiple sclerosis; Person-focused care; Relapsing-remitting multiple sclerosis

Mesh:

Year:  2018        PMID: 30476873     DOI: 10.1016/j.msard.2018.11.016

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  6 in total

1.  The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.

Authors:  Edward J D Webb; David Meads; Ieva Eskytė; Helen L Ford; Hilary L Bekker; Jeremy Chataway; George Pepper; Joachim Marti; Yasmina Okan; Sue H Pavitt; Klaus Schmierer; Ana Manzano
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

2.  "I Will Respect the Autonomy of My Patient": A Scoping Review of Shared Decision Making in Multiple Sclerosis.

Authors:  Anne Christin Rahn; Alessandra Solari; Heleen Beckerman; Richard Nicholas; David Wilkie; Christoph Heesen; Andrea Giordano
Journal:  Int J MS Care       Date:  2020-12-28

3.  A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping.

Authors:  Barry A Singer; Shannon Keith; Amy Howerter; Helen Doll; Timothy Pham; Rina Mehta
Journal:  Patient Prefer Adherence       Date:  2021-05-12       Impact factor: 2.711

Review 4.  A realist review of advance care planning for people with multiple sclerosis and their families.

Authors:  Laura Cottrell; Guillaume Economos; Catherine Evans; Eli Silber; Rachel Burman; Richard Nicholas; Bobbie Farsides; Stephen Ashford; Jonathan Simon Koffman
Journal:  PLoS One       Date:  2020-10-16       Impact factor: 3.240

5.  Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies.

Authors:  Hiba El Masri; Treasure M McGuire; Christine Dalais; Mieke van Driel; Helen Benham; Samantha A Hollingworth
Journal:  J Med Libr Assoc       Date:  2022-04-01

6.  Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.

Authors:  Gavin Giovannoni; Giancarlo Comi; Kottil Rammohan; Peter Rieckmann; Fernando Dangond; Birgit Keller; Dominic Jack; Patrick Vermersch
Journal:  Adv Ther       Date:  2021-08-09       Impact factor: 4.070

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.